Press ReleasesJournal Of Cellular And Molecular Medicine Publish Academic Paper...

Journal Of Cellular And Molecular Medicine Publish Academic Paper On Effect Of ArtemiC In Patients With COVID-19

-

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of phytomedicines, has had a peer reviewed paper into the Effect of ArtemiC in patients with COVID-19 published in the Journal of Cellular and Molecular Medicine.

Key Highlights:

  • Journal of Cellular and Molecular Medicine have published a study into the effect of MGC Pharma’s proprietary product ArtemiC™ in patients with Covid-19.
  • The Phase II prospective study is peer reviewed and is available for all to read
  • This is the first clinical study addressing the safety and tolerability of ArtemiC oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients.
  • These findings suggest that ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19.

The Phase II prospective study of 50 patients all with COVID-19 concludes that “ArtemiC curbed deterioration, possibly by limiting the cytokine storm of COVID-19, and bears great promise for COVID-19 patients, particularly in those with comorbidities.”

This is the first clinical study addressing the safety and tolerability of ArtemiC™ oral spray and its efficacy in improving symptoms in hospitalized COVID-19 patients and the first scientific article published on ArtemiC™.

The article is open access, and can be read in the Journal of Cellular and Molecular Medicine at the link below: https://onlinelibrary.wiley.com/doi/10.1111/jcmm.17337

Latest news

MGC Pharmaceuticals Releases Update On CimetrA Clinical Trial Progress In USA

MGC Pharmaceuticals Ltd (ASX, LSE: MXC, ‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development...

European Cannabis Stocks Review: Akanda’s ‘Concerned Shareholders’ Oust All Directors Except CEO To Prevent ‘Potentially Irreparable Harm’ – More From Goodbody Health & Chill...

It has been another week of positive developments for the cannabis industry across Europe, with yet more markets making...

Analysis Shows UK Market Could Grow To Over £1bn By 2026 As London Prepares To Host Europe’s Leading Cannabis Conference

ANALYSIS shows UK market could grow to over £1bn by 2026 as London prepares to host Europe’s leading cannabis...

Medical Cannabis Could Be Available In Spain By The End Of The Year

SPAIN could now see the regulation and distribution of medical cannabis rolled out before the end of the year...

New UK Company Heralds Its ‘Unique’ Medical Cannabis Delivery Mechanism

CANNABIS extraction and formulations specialist 113 Botanicals is in the process of securing Good manufacturing Practice (GMP) compliance for...

German Cannabis Bill By Year End With Adult-Use Launch Likely In Early 2024

GERMANY’s draft cannabis law should be ready by the end of the year with the launch of its adult-use...

Must read

You might also likeRELATED
Recommended to you